Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism

Journal of Pathology

Volumn 218, Issue 1, 2009, Pages 76-85

  Wang, Hongxia ^a   Liu, Bingbing ^b   Zhang, Chao ^a   Peng, Guoyuan ^a   Liu, Min ^a   Li, Dengwen ^a   Gu, Feng ^b   Chen, Quan ^a   Dong, Jin Tang ^a   Fu, Li ^b   Zhou, Jun ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Microtubule; Paclitaxel; Parkin; Sensitivity

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 9; PACLITAXEL; PARKIN; SUBTILISIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROTUBULE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; MICROTUBULES; PACLITAXEL; PROTEIN BINDING; STATISTICS, NONPARAMETRIC; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES;

EID: 66749185308     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2512     Document Type: Article

References (29)

1. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-608.
2. Smith DI, Zhu Y, McAvoy S, Kuhn R. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006;232(1):48- 57.
3. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle- associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97(24):13354-13359.
4. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105(7):891-902.
5. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trocken- bacher A, Schneider R, et al. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293(5528):263-269.
6. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the a-synuclein-interacting protein, synphilin- 1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001;7(10):1144-1150.
7. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
8. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003;100(10):5956-5961.
9. Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 2003;22(51):8370-8378.
10. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004;40(2):85-96.
11. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 2004;10(8):2720-2724.
12. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 2006;118(8):1945-1953.
13. Ren Y, Zhao J, Feng J. Parkin binds to a/p tubulin and increases their ubiquitination and degradation. JNeurosci 2003;23(8):3316- 3324.
14. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J. Parkin stabilizes microtubules through strong binding mediated by three independent domains. JBiolChem2005;280(17):17154-17162.
15. Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006;12(6):469-476.
16. Sun L, Gao J, Dong X, Liu M, Li D, Shi X, et al. EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci USA 2008;105(20):7153-7158.
17. Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, et al. Examination of in vitro chemosensi- tivity test using collagen gel droplet culture method with colorimet- ric endpoint quantification. Jpn J Cancer Res 2001;92(2):203-210.
18. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999;84(3):239-243.
19. Amos LA, Schlieper D. Microtubules and maps. Adv Protein Chem 2005;71257-298.
20. Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 2001;62(11):1469-1480.
21. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62(23):6864-6869.
22. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of pacli- taxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102(23):8315-8320.
23. Jordan MA, Wilson L. The use and action of drugs in analyzing mitosis. Methods Cell Biol 1999;61267-295.
24. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003;4(12):938-947.
25. LiuM, AnejaR, LiuC, SunL, GaoJ, WangH, et al. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. JBiol Chem 2006;281(26):18090-18097.
26. Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM. Parkin mediates the degradation-independent ubiquitination of Hsp70. JNeurochem 2008;105(5):1806-1819.
27. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007;26(2):298-307.
28. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-265.
29. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13(10):2849-2854.